SCOPUS 정보 검색 플랫폼

Volumn 28, Issue 1, 2001, Pages 108-112

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis

(7) Zegels, B a Eastell, R b Russell, R G G b Ethgen, D c Roumagnac, I c Collette, J a Reginster, J Y a,d

a UNIVERSITY OF LIÈGE (Belgium)

b UNIVERSITY OF SHEFFIELD (United Kingdom)

c PROCTER AND GAMBLE PHARMACEUTICALS (United States)

d WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases (Belgium)

Author keywords

Bisphosphonates; Collagen cross link; Osteoporosis; Parathyroid hormone (PTH); Risedronate; Treatment

Indexed keywords

COLLAGEN; CREATININE; DEOXYPYRIDINOLINE; PARATHYROID HORMONE; PLACEBO; PYRIDINOLINE; RISEDRONIC ACID;

ADULT; ARTICLE; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN METABOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SPINE; VERTEBRA FRACTURE;

AGED; CALCIUM CHANNEL BLOCKERS; COLLAGEN; CROSS-LINKING REAGENTS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; SPINAL DISEASES;

EID: 0035139987 PISSN: 87563282 EISSN: None Source Type: Journal
DOI: 10.1016/S8756-3282(00)00410-5 Document Type: Article

Times cited : (16)

References (18)

1
- 8044235628
- Dose-response relationships for alendronate treatment in osteoporotic elderly women
- (1997) J Clin Endocrinol Metab , vol.82 , pp. 265-274
- Bone, H.¹ Downs, R.² Tucci, J.³ Harris, S.⁴ Weinstein, R.⁵ Licata, A.⁶ McClung, M.⁷ Kimmel, D.⁸ Gertz, B.⁹ Hale, E.¹⁰ Polvino, W.¹¹

2
- 0032965138
- Risedronate, a highly effective, short-term oral treatment for Paget's disease: A dose-response study
- (1999) Calcif Tissue Int , vol.64 , pp. 93-99
- Brown, J.¹ Hosking, D.² Sainte-Marie, L.³ Johnston, C.⁴ Reginster, J.Y.⁵ Ryan, W.⁶ Johnson, T.⁷ Bekker, P.⁸

3
- 0029116697
- Alendronate treatment of the postmenopausal osteoporotic woman; Effect of multiple dosages on bone mass and bone remodeling
- (1995) Am J Med , vol.99 , pp. 144-152
- Chesnut, C.¹ McClung, M.² Ensrud, K.³ Bell, N.⁴ Genant, H.⁵ Harris, S.⁶ Singer, F.⁷ Stock, J.⁸ Yood, R.⁹ Delmas, P.¹⁰ Kher, U.¹¹ Pryor-Tillotson, S.¹² Santora, A.¹³

4
- 0030749171
- A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis
- (1997) Osteopor Int , vol.7 , pp. 488-495
- Clemmesen, B.¹ Ravn, P.² Zegels, B.³ Taquet, A.N.⁴ Christiansen, C.⁵ Reginster, J.Y.⁶

5
- 0031057249
- Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer; A double-blind, placebo-controlled study
- (1997) J Clin Oncol , vol.15 , pp. 955-962
- Delmas, P.¹ Balena, R.² Confravreux, E.³ Hardouin, C.⁴ Hardy, P.⁵ Bremond, A.⁶

6
- 0032893099
- Ibandronate
- (1999) Drugs , vol.57 , pp. 101-108
- Dooley, M.¹ Balfour, J.²

8
- 0033552255
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis
- (1999) JAMA , vol.282 , pp. 1344-1352
- Harris, S.¹ Watts, N.² Genant, H.³ McKeever, C.⁴ Hangartner, T.⁵ Keler, M.⁶ Chestnut, C.⁷ Brown, J.⁸ Eriksen, E.⁹ Hoseyni, M.¹⁰ Axelrod, D.¹¹ Miller, P.¹²

9
- 0028851590
- Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
- (1995) N Engl J Med , vol.333 , pp. 1437-1443
- Liberman, U.¹ Weiss, S.² Broll, J.³ Minne, H.⁴ Quan, H.⁵ Bell, N.⁶ Rodriguez-Portales, J.⁷ Downs, R.⁸ Dequeker, J.⁹ Favus, M.¹⁰ Seeman, E.¹¹ Recker, R.¹² Capizzi, T.¹³ Santora, A.¹⁴ Lombardi, A.¹⁵ Shah, R.¹⁶ Hirsch, L.¹⁷ Karpf, D.¹⁸

10
- 0028606037
- Pamidronate; An unrecognized problem in gastrointestinal tolerability
- (1994) Osteopor Int , vol.4 , pp. 320-322
- Lufkin, E.¹ Argueta, R.² Whitaker, M.³

11
- 0029021326
- Multiple ulcerative esophagitis caused by alendronate
- (1995) Am J Gastroenterol , vol.90 , pp. 1889-1890
- Maconi, G.¹ Porro, G.²

12
- 0031733092
- Risedronate increases bone mass in an early postmenopausal population; Two years of treatment plus one year of follow-up
- (1998) J Clin Endocrin Metab , vol.83 , pp. 396-402
- Mortensen, L.¹ Charles, P.² Bekker, P.³ DiGennaro, J.⁴ Johnston, C.⁵

13
- 0006339666
- Reginster, J.-Y., Gosset, C., and Fraikin, G. Bisphosphonates for the treatment of osteoporosis. In: Meunier, P. J., Ed. Osteoporosis: Diagnosis and Management. London: Martin Dunitz; 1998; 123-130.

14
- 12944291524
- Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
- (2000) Osteopor Int , vol.11 , pp. 83-91
- Reginster, J.Y.¹ Minne, H.² Sorensen, O.³ Hooper, M.⁴ Roux, C.⁵ Brandi, M.⁶ Lund, B.⁷ Ethgen, D.⁸ Pack, S.⁹ Roumagnac, I.¹⁰ Eastell, R.¹¹

15
- 0032942599
- Bisphosphonates; Pharmacology, mechanisms of action and clinical uses
- (1999) Osteopor Int , vol.9 , Issue.SUPPL. 2
- Russell, R.¹ Croucher, P.² Rogers, M.³

16
- 0031762884
- Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease
- (1998) J Clin Endocrinol Metab , vol.83 , pp. 1906-1910
- Singer, F.¹ Clemens, T.² Eusebio, R.³ Bekker, P.⁴

17
- 0029561513
- Sustained response to intravenous alendronate in postmenopausal osteoporosis
- (1995) Bone , vol.17 , Issue.SUPPL. 6 , pp. 517-520
- Vasikaran, S.D.¹ Khan, S.² McCloskey, E.V.³ Kanis, J.A.⁴

18
- 0006325976
- Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis
- (1999) J Bone Miner Res , vol.14 , Issue.SUPPL. 136 , pp. 1016
- Watts, N.¹ Roux, C.² Genant, H.³ Adami, S.⁴ Hangartner, T.⁵ Miller, P.⁶ Sorensen, O.⁷ Hooper, M.⁸ Ethgen, D.⁹ Valent, D.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.